8 April 2025 - Bayer has submitted an application to the EMA seeking approval of aflibercept 8 mg (114.3 mg/ml solution for injection) for the treatment of patients with macular oedema following retinal vein occlusion including central, branch and hemi-retinal vein occlusion. 

This would be the third indication for aflibercept 8 mg supporting the blockbuster status of Eylea.

Read Bayer press release